Company Overview and News

 
I-Cable Tumbles by the Most Ever After Wharf to End Support - Bloomberg

2017-03-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
HK tycoon Woo's Wharf agrees to sell telecom unit to TPG, MBK for US$1.2 bil - source

2016-10-04 theedgemarkets
HONG KONG (Oct 4): Hong Kong tycoon Peter Woo's Wharf Holdings Ltd has agreed to sell its telecom business to a consortium of private equity firms TPG Capital Management LP and MBK Partners Inc for HK$9.5 billion (US$1.22 billion), a person familiar with the matter told Reuters on Tuesday.

 
UPDATE 1-HK tycoon Woo's Wharf agrees to sell telecom unit to TPG, MBK for $1.2 bln -source

2016-10-04 reuters
* Sale includes Wharf T&T, but not broadcaster I-Cable (Adds Wharf T&T results, strategic review, share performance)

 
Hong Kong tycoon Woo's Wharf agrees to sell telecom unit to TPG, MBK for $1.2 billion: source

2016-10-04 reuters
HONG KONG Hong Kong tycoon Peter Woo's Wharf Holdings Ltd (0004.HK) has agreed to sell its telecom business to a consortium of TPG Capital Management LP and MBK Partners for HK$9.5 billion ($1.22 billion), a person familiar with the matter told Reuters on Tuesday.

 
Hong Kong tycoon Woo's Wharf agrees to sell telecom unit to TPG, MBK for US$1.2 billion: source

2016-10-04 channelnewsasia
HONG KONG: Hong Kong tycoon Peter Woo's Wharf Holdings Ltd has agreed to sell its telecom business to a consortium of TPG Capital Management LP and MBK Partners for HKUS$9.5 billion (US$1.22 billion), a person familiar with the matter told Reuters on Tuesday.

 
Sale of Wharf's HK Telecom Unit Could Reportedly Reach Up to $1.2 Billion

2016-09-07 fortune
KKR & Co LP kkr and HKBN have placed final bids for the Hong Kong telecom arm of Wharf Holdings, warfy in a deal likely to fetch $1 billion to $1.2 billion, people familiar with the matter told Reuters.

 
HK tycoon Woo seeks bidders for US$1 bil-plus telecoms unit, from KKR to Anbang - sources

2016-06-13 www2.theedgemarkets
HONG KONG (June 13): Hong Kong tycoon Peter Woo's Wharf Holdings Ltd plans to sell its telecoms business in a deal that could be worth more than US$1 billion, people familiar with the matter said, and has asked more than a dozen potential suitors, including both giant Chinese insurers and Western buyout firms, to submit bids.

 
Exclusive: HKs's Wharf Holdings seeks buyers for telecoms unit, sale may fetch more than $1 billion - sources

2016-06-13 reuters
HONG KONG Hong Kong tycoon Peter Woo's Wharf Holdings Ltd plans to sell its telecoms business in a deal that could be worth more than $1 billion, people familiar with the matter said, and has asked more than a dozen potential suitors, including both giant Chinese insurers and Western buyout firms, to submit bids.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...